Zhong Zheng Wang·2025-12-11 10:37Core Viewpoint - Shanghai Pharmaceuticals has received approval for its innovative drug, Sitojilun, aimed at treating primary hypertension, marking a significant achievement in its commitment to independent innovation in the pharmaceutical industry [1][2]. Group 1: Product Approval and Market Strategy - The innovative drug Sitojilun (SPH3127), a new generation oral non-peptide small molecule renin inhibitor, has been approved for market launch, addressing unmet clinical needs in hypertension treatment [1]. - Shanghai Pharmaceuticals has established a comprehensive distribution network covering over 80,000 medical institutions across 25 provinces, municipalities, and autonomous regions in China, ensuring effective market access for Sitojilun [1]. Group 2: Research and Development Investment - In 2024, Shanghai Pharmaceuticals plans to invest 2.818 billion yuan in R&D, positioning itself among the industry leaders in investment intensity [2]. - As of the end of Q3 2025, the company has submitted 57 new drug applications for clinical trials, with 45 of these being innovative drugs, demonstrating a robust pipeline and commitment to long-term innovation [2]. Group 3: Collaborative Innovation Ecosystem - The company has established the Shanghai Frontier Life Science Innovation Center to foster collaboration with top universities and research institutions, creating an open innovation ecosystem [3]. - Since its launch in September of last year, the center has attracted numerous renowned research institutions and pharmaceutical companies, enhancing the innovation landscape [3]. - Shanghai Pharmaceuticals aims to continue investing in R&D focused on urgent clinical needs in areas such as oncology, immunology, cardiovascular health, and infectious diseases, with the goal of transforming innovative results into marketable products [3].